

8-28-3

1653



PTO-SB-21 (05-03)

Approved for use through 04/30/2003 OMB 0651-0031

U S Patent and Trademark Office U S DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	09/847940-Conf. #6156
		Filing Date	May 2, 2001
		First Named Inventor	Michael J. May
		Art Unit	1653
		Examiner Name	R. Mitra
Total Number of Pages in This Submission	1	Attorney Docket Number	YAI-001CP

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Response to Restriction Requirement; Statement of Limited Recognition Under 37 CFR 10.9(b); Return Postcard
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	<input type="checkbox"/> Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT


Firm or Individual name	LAHIVE & COCKFIELD, LLP Maria Laccotripe Zacharakis, Ph.D., J.D. - LRA
Signature	
Date	August 25, 2003

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 244 880 224 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: August 25, 2003

Signature:

(Maria Laccotripe Zacharakis, Ph.D.)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

the application of: Michael J. May *et al.*

Serial No.: 09/847,940

Filed: May 2, 2001

For: *ANTI-INFLAMMATORY COMPOUNDS AND
USES THEREOF*

Attorney Docket No.: YAI-001CP (formerly PPI-117)

Group Art Unit: 1653

Examiner: Mitra, Rita


Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

"Express Mail" Mailing Label Number EV 244 880 224 US

Date of Deposit August 25, 2003

I hereby certify that this transmittal letter and the papers referred to as being enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450

Signature


Maria Laccotripe Zacharakis, Ph.D.

Please Print Name of Person Signing

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

This is in response to the Office Action dated July 23, 2003 (Paper No. 13) setting forth a restriction requirement.

The Examiner has required restriction to one of the following inventions under 35 U.S.C. §121:

I. Claims 1-13 and 27-34, drawn to a method of modulating NF- κ B induction in a cell by contacting a cell with an anti-inflammatory compound comprising at least one NEMO binding domain, wherein the said compound is capable of blocking the interaction between IKK and NEMO; a method of treating a subject suffering from inflammatory disorder comprising administering an anti-inflammatory compound, classified in class 514, subclass 2. Should Group I be elected, applicants are required to select one sequence of peptides of SEQ ID Nos: 2, 4-6, 11-12, 16-17.